New Classifications of Five Distinct “Sleep” Profi... ...
Science in the Age of AI | AI for Science Forum...
Ask the Heart Doctor | Heart Valve Disease and Sur...
High-speed imaging tracks live brain cell activity...
NAD⁺ restores memory in Alzheimer's disease models...
Mark Cuban: A Master Disrupter for American Health...
Teen girls facing the most adversity showed the biggest gain...
September 15,2026
Specialized imaging reveals hormone-driven brain changes...
September 14,2026
Submillimeter MRI reveals brain hubs that guide risky decisi...
September 12,2026
Risk of herpes zoster among breast cancer survivors in Japan...
September 11,2026
Three proteins help organs tailor shared circadian clock to ...
September 10,2026
Should you worry about melatonin and heart failure? The evid...
December 02,2025
Category
Traditional Medicine
Q & A
Wellness
Drug Discovery
Technology & AI
Clinical Pearl Series
Breakthroughs
Immunology & Rheumatology
Reproduction
Hepatobiliary&Pancreas Surgery
Most Read
Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and SexAverage Ranges Show Normal Pressure On the ArteriesBySheryl Huggins SalomonUpdated on April 21, 2023Medically reviewed byJeffre
Cardiovascular Diseases April 07,2024
Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and SexAverage Ranges Show Normal Pressure On the ArteriesBySheryl Huggins SalomonUpdated on April 21, 2023Medically reviewed byJeffre
Cardiovascular Diseases April 07,2024
Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals has commenced dosing the first patients in its Phase 2a clinical trial for PP405, a novel topical treatment designed to reactivate dormant hair follicle stem cells.
Dermatology August 14,2024
Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals has commenced dosing the first patients in its Phase 2a clinical trial for PP405, a novel topical treatment designed to reactivate dormant hair follicle stem cells.
Dermatology August 14,2024
Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs MeanWhat to Know About Your Blood TypeByNancy LeBrunPublished on September 15, 2023Medically reviewed byAnju Goel, MDYou
Oncology March 17,2024
Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs MeanWhat to Know About Your Blood TypeByNancy LeBrunPublished on September 15, 2023Medically reviewed byAnju Goel, MDYou
Oncology March 17,2024
Today's News
GOSH BRC Showcase 2025 - Genomic medicine...
Can a twice-a-year shot help end the HIV...
Announcement of the 2025 Nobel Prize in ...
Reprogramming Stem Cells Could Cure Type...
Why MDMA did NOT get FDA approval...
More News
ChatGPT may be better than doctors at evidence-based management of clinical depression

ChatGPT may be better than doctors at evidence-based management of clinical depression

byBritish Medical JournalCredit: Unsplash/CC0 Public DomainChatGPT, the AI language model capable of mirroring human conversation, may be better than a doctor at following recognized treatment s
Psychiatry & Mental Health October 17,2023
ChatGPT may be better than doctors at evidence-based management of clinical depression

ChatGPT may be better than doctors at evidence-based management of clinical depression

byBritish Medical JournalCredit: Unsplash/CC0 Public DomainChatGPT, the AI language model capable of mirroring human conversation, may be better than a doctor at following recognized treatment s
Psychiatry & Mental Health October 17,2023
Despite good oral hygiene, local oral inflammation can also affect the mouth

Despite good oral hygiene, local oral inflammation can also affect the mouth

by Stephanie Baum , Medical XpressEG incorporating a split mouth design reveals control sites are not static and vary by IRT. (A) Study overview highlighting the clinical EG model. (B) Proportion of c
Stomatology October 17,2023
Despite good oral hygiene, local oral inflammation can also affect the mouth

Despite good oral hygiene, local oral inflammation can also affect the mouth

by Stephanie Baum , Medical XpressEG incorporating a split mouth design reveals control sites are not static and vary by IRT. (A) Study overview highlighting the clinical EG model. (B) Proportion of c
Stomatology October 17,2023
Brain fungal infection produces Alzheimer's disease-like changes, says new study

Brain fungal infection produces Alzheimer's disease-like changes, says new study

by Homa Warren,Baylor College of MedicineGraphical abstract. Credit:Cell Reports(2023). DOI: 10.1016/j.celrep.2023.113240Previous research has implicated fungi in chronic neurodegene
Neurology October 17,2023
Brain fungal infection produces Alzheimer's disease-like changes, says new study

Brain fungal infection produces Alzheimer's disease-like changes, says new study

by Homa Warren,Baylor College of MedicineGraphical abstract. Credit:Cell Reports(2023). DOI: 10.1016/j.celrep.2023.113240Previous research has implicated fungi in chronic neurodegene
Neurology October 17,2023
Key Factors to Consider in the Management of Tumor Lysis Syndrome

Key Factors to Consider in the Management of Tumor Lysis Syndrome

February 22, 2023Brittany LovelyFor patients with aggressive malignant tumors and high tumor burden, onco- logic emergencies such as tumor lysis syndrome emerge as a disease symptom or a treat- ment-r
Oncology October 15,2023
Key Factors to Consider in the Management of Tumor Lysis Syndrome

Key Factors to Consider in the Management of Tumor Lysis Syndrome

February 22, 2023Brittany LovelyFor patients with aggressive malignant tumors and high tumor burden, onco- logic emergencies such as tumor lysis syndrome emerge as a disease symptom or a treat- ment-r
Oncology October 15,2023
PD-1/VEGFR-2 Inhibitor Combo Shows Durable Responses in Nasopharyngeal Carcinoma

PD-1/VEGFR-2 Inhibitor Combo Shows Durable Responses in Nasopharyngeal Carcinoma

February 10, 2023Ashling WahnerThe combination of camrelizumab and apatinib led to long-term antitumor activity with manageable toxicities in patients with recurrent or metastatic nasopharyngeal carci
Oncology October 15,2023
PD-1/VEGFR-2 Inhibitor Combo Shows Durable Responses in Nasopharyngeal Carcinoma

PD-1/VEGFR-2 Inhibitor Combo Shows Durable Responses in Nasopharyngeal Carcinoma

February 10, 2023Ashling WahnerThe combination of camrelizumab and apatinib led to long-term antitumor activity with manageable toxicities in patients with recurrent or metastatic nasopharyngeal carci
Oncology October 15,2023
AFM24 Plus Atezolizumab Shows Acceptable Safety, Early Activity in EGFR+ Solid Tumors

AFM24 Plus Atezolizumab Shows Acceptable Safety, Early Activity in EGFR+ Solid Tumors

January 14, 2023Ryan ScottA doublet comprised of the bispecific innate cell engager AFM24 and atezolizumab had a tolerable safety profile and elicited responses in patients with advanced EGFR-expressi
Oncology October 15,2023
AFM24 Plus Atezolizumab Shows Acceptable Safety, Early Activity in EGFR+ Solid Tumors

AFM24 Plus Atezolizumab Shows Acceptable Safety, Early Activity in EGFR+ Solid Tumors

January 14, 2023Ryan ScottA doublet comprised of the bispecific innate cell engager AFM24 and atezolizumab had a tolerable safety profile and elicited responses in patients with advanced EGFR-expressi
Oncology October 15,2023
AstraZeneca to Discontinue Moxetumomab Pasudotox in US for Hairy Cell Leukemia

AstraZeneca to Discontinue Moxetumomab Pasudotox in US for Hairy Cell Leukemia

January 13, 2023Chris RyanMoxetumomab pasudotox-tdfk will be permanently discontinued in the United States market for the treatment of relapsed/refractory hairy cell leukemia.Hairy Cell Leukemia (Kate
Oncology October 15,2023
AstraZeneca to Discontinue Moxetumomab Pasudotox in US for Hairy Cell Leukemia

AstraZeneca to Discontinue Moxetumomab Pasudotox in US for Hairy Cell Leukemia

January 13, 2023Chris RyanMoxetumomab pasudotox-tdfk will be permanently discontinued in the United States market for the treatment of relapsed/refractory hairy cell leukemia.Hairy Cell Leukemia (Kate
Oncology October 15,2023
Fox Chase Physician Wins Best Poster Award at Breast Cancer Meeting for Research on Surgery to

Fox Chase Physician Wins Best Poster Award at Breast Cancer Meeting for Research on Surgery to

May 26, 2023Fox Chase Cancer CenterAustin D. Williams, MD, MSEd, of Fox Chase Cancer Center, received the Best Poster Award at the recent 24th Annual Meeting of the American Society of Breast Surgeons
Oncology October 15,2023
Fox Chase Physician Wins Best Poster Award at Breast Cancer Meeting for Research on Surgery to

Fox Chase Physician Wins Best Poster Award at Breast Cancer Meeting for Research on Surgery to

May 26, 2023Fox Chase Cancer CenterAustin D. Williams, MD, MSEd, of Fox Chase Cancer Center, received the Best Poster Award at the recent 24th Annual Meeting of the American Society of Breast Surgeons
Oncology October 15,2023
Enfortumab Vedotin Plus Pembrolizumab Generates Survival Benefit in Previously Untreated

Enfortumab Vedotin Plus Pembrolizumab Generates Survival Benefit in Previously Untreated

September 22, 2023Chris RyanTreatment with the combination of enfortumab Vedotin and pembrolizumab led to an improvement in overall survival and progression-free survival compared with chemotherapy in
Oncology October 15,2023
Enfortumab Vedotin Plus Pembrolizumab Generates Survival Benefit in Previously Untreated

Enfortumab Vedotin Plus Pembrolizumab Generates Survival Benefit in Previously Untreated

September 22, 2023Chris RyanTreatment with the combination of enfortumab Vedotin and pembrolizumab led to an improvement in overall survival and progression-free survival compared with chemotherapy in
Oncology October 15,2023
Venetoclax/Atezolizumab/Obinutuzumab Elicits Durable Responses in Richter Transformation

Venetoclax/Atezolizumab/Obinutuzumab Elicits Durable Responses in Richter Transformation

June 23, 2023Ryan ScottThe combination of venetoclax, atezolizumab, and obinutuzumab elicited responses and prolonged time progression, in patients with chronic lymphocytic leukemia with Richter trans
Oncology October 15,2023
Venetoclax/Atezolizumab/Obinutuzumab Elicits Durable Responses in Richter Transformation

Venetoclax/Atezolizumab/Obinutuzumab Elicits Durable Responses in Richter Transformation

June 23, 2023Ryan ScottThe combination of venetoclax, atezolizumab, and obinutuzumab elicited responses and prolonged time progression, in patients with chronic lymphocytic leukemia with Richter trans
Oncology October 15,2023
More News
Week’s Top
Podcasts
... Health spending has been rising across rich countries with different systems ... ... GOSH BRC Showcase 2025 - Genomic medicine ... ... At what age do people experience depression for the first time? Depression can affect people over long periods of their lives. Some people experience this condition continuously, while for others, it occu...
FIND US ON
ABOUT
Who We Are
Contact Us
Editorial Team
Sitemap
Policy
Privacy Policy
Advertising Policy
Editorial Policy
Corrections Policy
Medical Disclaimer
Alliance
wmo.com
sleep.net
pharm.net
doctors.net
worldsleep.com